Abstract 44P
Background
Management of Her-2 negative breast cancer is evolving. Literature on response and outcomes to neoadjuvant chemotherapy (NACT) is limited from the Indian subcontinent. In this study, we evaluated the pathological complete response(pCR) rates to NACT, and outcomes in Her2-negative breast cancers, which includes TNBC and hormone receptor-positive (HR+) cohorts.
Methods
Her2-negative breast cancer patients who received neoadjuvant chemotherapy and then underwent surgery between January 2017 and December 2021 at a tertiary cancer hospital in India were included. Pathological response to chemotherapy, and outcomes were noted by retrospective electronic medical record review. pCR was defined as complete disappearance of all invasive carcinoma cells in the breast and axillary lymph nodes (ypT0/ypN0).
Results
Of the 1760 Her-2 negative breast cancers who were registered at our institute in the above time period, 232 patients received NACT, and 172 patients who completed NACT and then underwent surgery were included in the analysis. The median age of presentation was 50 years (Range 31-74 years). The median age was 46 years in the TNBC cohort, and 55 years in HR+ cohort. Majority of the patients received anthracycline/taxane based chemotherapy, and 94.1% (162/172) of the patients received all planned cycles of chemotherapy before surgery. Overall pathological complete response (pCR) was seen in 27.3% of patients (47/175). pCR rates were significantly higher in the TNBC cohort compared to HR+ cohort (38.2% vs 15.6 %, P - 0.001). TNBC variant and higher histologic grade (Grade III) were associated with significantly higher pCR rates. At a median follow-up of 30.8 months, 23.2% of patients (40/172) developed relapse (26.9% in TNBC, 19.2 % in HR+). Patients who achieved pCR had significantly lower chances of recurrence compared to those with non-pCR to chemotherapy (12.7% vs 27.2%, P- 0.045).
Conclusions
Triple-negative breast cancer subtype and higher histologic grade are associated with significantly higher pathological complete response to NACT. Achieving complete pathological response is associated with lower risk of breast cancer recurrence, and it is an important surrogate marker for recurrence-free and overall survival.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
442P - Negative impact on bone homeostasis in postmenopausal women with non-metastatic breast cancer during cytotoxic chemotherapy
Presenter: Yadav Nisha
Session: Poster Display
Resources:
Abstract
443P - Efficacy of vitamin D supplementation in overall survival of cancer patients: Systematic review and meta-analysis
Presenter: Visakha Irawan
Session: Poster Display
Resources:
Abstract
444P - Commencing a nurse led symptom and urgent review clinic (SURC) in a Victorian regional cancer centre
Presenter: Sue Bartlett
Session: Poster Display
Resources:
Abstract
445P - Self-reported symptom burden, quality of life and unmet need of symptom management in nasopharyngeal cancer survivors: A cross-sectional survey
Presenter: Jerry Ching
Session: Poster Display
Resources:
Abstract
446P - A single center experience of anamorelin in patients with non-small cell lung cancer
Presenter: Takanori Ito
Session: Poster Display
Resources:
Abstract
447P - Quality of life in patients with EGFR-mutated lung cancer receiving gefitinib vs gefitinib plus pemetrexed and carboplatin chemotherapy
Presenter: Nandini Menon
Session: Poster Display
Resources:
Abstract
448P - Association of clinicopathological characteristics and pro-inflammatory markers with reduced relative dose intensity in breast cancer chemotherapy
Presenter: Susanna Hutajulu
Session: Poster Display
Resources:
Abstract
449P - Psychometric validation of the MD Anderson symptom inventory head&neck module: Chinese version in nasopharyngeal cancer survivors
Presenter: Victor Tam
Session: Poster Display
Resources:
Abstract
450P - Retrospective study of anamorelin therapy for unresectable or recurrent pancreatic cancer with cancer cachexia
Presenter: Mao Okada
Session: Poster Display
Resources:
Abstract
451P - The real-world efficacy and safety of anamorelin hydrochloride for Japanese unresectable non-small cell lung cancer patients with cachexia
Presenter: Daisuke Arai
Session: Poster Display
Resources:
Abstract